新辅助放化疗联合手术治疗ⅠB2~ⅡA2期子宫颈癌临床预后因素分析

doi:10.3969/j.issn.1007-3969.2016.05.013

中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (5): 427-433.doi: 10.3969/j.issn.1007-3969.2016.05.013

新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析

刘　健¹，崔艳艳²，李胜泽¹，马　玲¹，李　群¹，李玉芝¹，郭苏阳¹，刘静波¹

1. 蚌埠医学院第一附属医院妇瘤科，安徽蚌埠 233004 ；
2. 怀远县第二人民医院妇产科，安徽怀远 233400

出版日期:2016-05-30 发布日期:2016-06-23
通信作者: 刘健　E-mail：Elitelj@126.com
基金资助:
安徽省自然科学基金(KJ2015B0966Y)。

Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery

LIU Jian¹, CUI Yanyan², LI Shengze¹, MA Ling¹, LI Qun¹, LI Yuzhi¹, GUO Suyang¹, LIU Jingbo¹

1. Department of Gynecological Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China; 2. Department of Gynecology and Obstetrics, the Second People’s Hospital of Huaiyuan County, Huaiyuan 233400, Anhui Province, China

Published:2016-05-30 Online:2016-06-23
Contact: LIU Jian E-mail: Elitelj@126.com

文章分享

摘要/Abstract

摘要： 背景与目的：探讨Ⅰ_B2～Ⅱ_A2期子宫颈腺癌与腺鳞癌经新辅助放化疗联合手术治疗后的生存及复发情况，并分析其预后影响因素。方法：收集蚌埠医学院第一附属医院2005年4月—2011年10月50例Ⅰ_B2～Ⅱ_A2期患者的临床病理资料。患者均接受广泛全子宫切除+盆腔淋巴结清扫术，且术前均接受1次静脉化疗，宫颈肿瘤直径大于等于6 cm，给予阴道腔内放疗1次。回顾分析患者的生存及复发情况，探讨其预后影响因素。结果：50例Ⅰ_B2～Ⅱ_A2期子宫颈腺癌和腺鳞癌患者中，随访期内死亡15例，2年和5年无进展生存率分别是80.12%和72.24%，中位无进展生存时间为68个月；2年和5年累积总生存率分别是95.38%和73.56%，中位总生存时间为80个月。单因素分析显示，盆腔淋巴结转移、宫颈间质浸润、宫旁浸润和新辅助放化疗后肿瘤最大直径缩短小于3 cm的患者预后较差(P<0.05)，而年龄、术后放化疗、淋巴管间隙受累分期、FIGO分期、是否保留卵巢和病理类型与预后无明显相关性(P>0.05)。多因素COX回归分析结果显示，盆腔淋巴结转移和放化疗后肿瘤直径缩小是宫颈腺癌和腺鳞癌的独立预后影响因素。结论：新辅助放化疗联合手术治疗提高了Ⅰ_B2～Ⅱ_A2期宫颈腺癌和腺鳞癌手术切除率，而盆腔淋巴结转移及放化疗后宫颈肿瘤最大径消退程度是宫颈腺癌和腺鳞癌的独立预后因素。

关键词: 子宫颈癌, 辅助放化疗, 子宫切除术, 预后

Abstract: Background and purpose: The aim of this study was to analyze the prognostic factors in uterine adenocarcinoma and adenosquamous carcinoma treated with a combination of neoadjuvant chemoradiotherapy and surgery. Methods: Clinicopathologic data from 50 patients with stageⅠ_B2-Ⅱ_A2 uterine cervical cancer were collected from the First Affiliated Hospital of Bengbu Medical College between Apr. 2005 and Oct. 2011. All patients underwent neoajuvant chemoradiotherapy, followed by radical hysterectomy and pelvic lymph node dissection. Before surgery, an intravenous chemotherapy was given. A particular vaginal brachytherapy was given to those with tumor diameter ≥6 cm. The survival and recurrence in patients were analyzed retrospectively to investigate the prognostic factors. Results: In 50 patients with Ⅰ_B2-Ⅱ_A2uterine adenocarcinoma and adenosquamous carcinoma, 15 died during the follow-up period. The 2-year and 5-year progression-free survival rates were 80.12% and 72.24%, respectively, and median progression-free survival was 68 months. The 2-year and 5-year overall survival rates were 95.38% and 73.56%, respectively, and median overall survival was 80 months. Univariate analysis revealed that pelvic lymph node metastasis, cervical stromal invasion, parametrial infiltration, tumor diameter reduction <3 cm and advanced stage were the prognostic factors in patients with cervical cancer (P<0.05). Age, postoperative radiochemotherapy, lymphatic clearance involvement, FIGO stage, preservation of ovary and pathologic type were not associated with prognosis (P>0.05). Multivariate Cox proportional analysis revealed that pelvic lymph node metastasis and tumor diameter reduction after radiation and chemotherapy were the independent prognostic factors in patients with cervical cancer. Conclusion: The combination of neoadjuvant chemotherapy and surgery improves the resectable rate of patients with Ⅰ_B2-Ⅱ_A2 uterine adenocarcinoma and adenosquamous carcinoma. Pelvic lymph node metastasis and tumor diameter reduction after radiation and chemotherapy are the independent prognostic factors in patients with cervical cancer.

Key words: Cervical cancer, Neoadjuvant chemotherapy, Hysterectomy, Prognosis

刘　健,崔艳艳,李胜泽,等. 新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析[J]. 中国癌症杂志, 2016, 26(5): 427-433.

LIU Jian, CUI Yanyan, LI Shengze, et al. Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery[J]. China Oncology, 2016, 26(5): 427-433.

[1]	伍雯, 张若昕, 翁俊勇, 马延磊, 蔡国响, 李心翔, 杨永志. 探索阳性淋巴结比率在ypⅢ期结直肠癌患者中的预后价值及预测模型的建立[J]. 中国癌症杂志, 2024, 34(9): 873-880.
[2]	肖锋, 许桐林, 朱琳, 肖静文, 吴天祺, 顾春燕. M1型肿瘤相关巨噬细胞在肝细胞癌组织中浸润的意义[J]. 中国癌症杂志, 2024, 34(8): 726-733.
[3]	唐楠, 黄慧霞, 刘晓健. 利用单细胞测序和转录组测序建立结直肠癌免疫细胞的9基因预后模型[J]. 中国癌症杂志, 2024, 34(6): 548-560.
[4]	张若昕, 叶紫岚, 翁俊勇, 李心翔. 高龄与Ⅱ期结直肠癌患者预后不良的相关性研究[J]. 中国癌症杂志, 2024, 34(5): 485-492.
[5]	刘志昱, 徐栋, 陈西昊, 李纪鹏. 局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建[J]. 中国癌症杂志, 2024, 34(2): 191-200.
[6]	李军, 陆亭伟, 方旭前. MSI-H/dMMR对BRAF V600E突变型的手术可切除结直肠癌患者的临床病理学特征及预后的影响[J]. 中国癌症杂志, 2024, 34(11): 1061-1066.
[7]	储亚娟, 张蕾, 李云海, 罗伟明, 张静, 莫晓晨, 马金利. 探讨氨磷汀对局部晚期直肠癌新辅助放疗同期伊立替康化疗的减毒作用：对154例病例的回顾性队列研究[J]. 中国癌症杂志, 2024, 34(10): 957-965.
[8]	金奕滋, 林明曦, 张剑. 乳腺癌原发灶与肝转移灶受体表达差异研究[J]. 中国癌症杂志, 2023, 33(9): 834-843.
[9]	吴晗, 杨章孺, 冯雯, 曾琬琴, 郭金栋, 李洪选, 王常禄, 王家明, 吕长兴, 张琴, 余雯, 蔡旭伟, 傅小龙. 多原发性早期肺癌立体定向放射治疗后疗效及患者预后分析[J]. 中国癌症杂志, 2023, 33(9): 844-856.
[10]	陈金娟, 王星然, 李文质, 程煜, 孙艺华, 陶祥, 马凤华, 孙莉, 赵洪波, 鹿欣. 保守手术治疗的10例Ⅰ期胎盘部位滋养细胞肿瘤病例报告及文献复习[J]. 中国癌症杂志, 2023, 33(9): 857-865.
[11]	孙洋, 王炼, 赵萌, 张小凤, 耿志军, 王月月, 宋雪, 左芦根, 李静, 胡建国. 胃癌中FKBP1A高表达的预后价值及其靶向PI3K/AKT对糖代谢的调控作用[J]. 中国癌症杂志, 2023, 33(8): 726-739.
[12]	姜琳, 刘绮颖, 贾利晴, 张静, 常恒, 薛田, 任敏, 柏乾明, 朱晓丽, 周晓燕. 胶质瘤中MGMT甲基化状态及其临床意义的回顾性研究[J]. 中国癌症杂志, 2023, 33(8): 740-750.
[13]	王若曦, 吉芃, 龚悦, 陈盛. HER2低表达乳腺癌新辅助化疗效果及其预后特征：一项单中心回顾性研究[J]. 中国癌症杂志, 2023, 33(7): 686-692.
[14]	左学良, 陈志强, 董润雨, 王智雄, 蔡娟. 联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J]. 中国癌症杂志, 2023, 33(5): 460-468.
[15]	董晓欢, 刘俊, 李洪选, 程妍, 李玥, 余雯, 蔡旭伟, 傅小龙. 食管癌新辅助放化疗中放疗累及野照射的初步研究[J]. 中国癌症杂志, 2023, 33(3): 267-273.

新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析

Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

新辅助放化疗联合手术治疗ⅠB2~ⅡA2期子宫颈癌临床预后因素分析

Analysis of prognostic factors in patients with stage ⅠB2-ⅡA2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

新辅助放化疗联合手术治疗Ⅰ_B2~Ⅱ_A2期子宫颈癌临床预后因素分析

Analysis of prognostic factors in patients with stage Ⅰ_B2-Ⅱ_A2 uterine cervical cancer treated with a combintion of neoadjuvant chemotherapy and surgery